Ocular Therapeutix's Chief Strategy Officer Resigns Effective Friday To Become A Private Company's CEO
Sanjay Nayak told the company of his decision Wednesday; an 8-K filed Friday says he is leaving to become CEO of a privately held company.
Ocular Therapeutix chief strategy officer Sanjay Nayak resigned, effective Friday, to become chief executive of a privately held company, according to an 8-K filed that day. He gave the company notice on Wednesday.
What the 8-K says
The filing, made under Item 5.02 (the section for departures of certain officers), says Sanjay Nayak, M.B.B.S., Ph.D., told Ocular Therapeutix on October 14 that he was resigning. The resignation took effect October 16, the same day the company signed and filed the report.
That makes the exit immediate rather than phased. The filing says he is leaving to become CEO of a privately held company and does not name it. Jason S. Robins, the company's chief financial officer, signed the filing.
Stock and what to watch
Ocular Therapeutix shares closed at $6.87 at Friday's close, down about 7% from $7.38 the prior session, according to market data. The filing was accepted at 4:15 p.m. ET, after that close.
The 8-K does not name a replacement for the strategy role.
The next filing from the company would show whether a successor is named for the chief strategy officer role.
Sources
- 8-K Filing — OCULAR THERAPEUTIX, INC (OCUL) — SEC EDGAR